CATALOGO DEI PRODOTTI DELLA RICERCA

VISCO, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.919
EU - Europa 2.213
AS - Asia 1.507
OC - Oceania 15
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 7
AF - Africa 6
AN - Antartide 1
Totale 6.679
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.900
CN - Cina 1.260
GB - Regno Unito 622
IE - Irlanda 360
FR - Francia 359
SE - Svezia 254
IT - Italia 187
SG - Singapore 152
DE - Germania 151
UA - Ucraina 122
FI - Finlandia 90
VN - Vietnam 41
RU - Federazione Russa 23
CA - Canada 15
AU - Australia 14
KR - Corea 14
BE - Belgio 13
TR - Turchia 8
EU - Europa 7
JP - Giappone 7
GR - Grecia 6
IN - India 6
HK - Hong Kong 5
NL - Olanda 5
BR - Brasile 4
CL - Cile 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
ID - Indonesia 3
MA - Marocco 3
AL - Albania 2
DK - Danimarca 2
MX - Messico 2
PT - Portogallo 2
SA - Arabia Saudita 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CH - Svizzera 1
CO - Colombia 1
CR - Costa Rica 1
ES - Italia 1
FK - Isole Falkland (Malvinas) 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MU - Mauritius 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 6.679
Salva come PNG Salva come JPEG
Città #
Southend 596
Chandler 577
Jacksonville 564
Dublin 355
Beijing 263
Ashburn 161
Lawrence 154
Princeton 154
Wilmington 154
Jinan 130
Woodbridge 113
Nanjing 111
Shenyang 109
Singapore 91
New York 81
Hebei 68
Houston 68
Tianjin 62
Helsinki 52
Zhengzhou 46
Sindelfingen 45
Taizhou 39
Haikou 36
Jiaxing 36
Redmond 36
Ann Arbor 35
Dearborn 35
Grafing 33
Changsha 32
Dong Ket 31
Ningbo 31
Verona 29
Hangzhou 28
Taiyuan 28
Guangzhou 26
Nanchang 25
Seattle 25
Lanzhou 24
Norwalk 24
Redwood City 22
Milan 18
Fuzhou 17
Seoul 14
Washington 14
Boardman 13
San Francisco 13
Brussels 10
Los Angeles 9
Toronto 9
Chicago 7
Fairfield 7
Falls Church 6
Kent 6
Lappeenranta 6
Melbourne 6
Vigasio 6
Bologna 5
Canberra 5
Mehlingen 5
Arezzo 4
Berlin 4
Padova 4
Pittsburgh 4
São Paulo 4
Atlanta 3
Cambridge 3
Carmignano di Brenta 3
Clearwater 3
Frankfurt am Main 3
Fremont 3
Groningen 3
Kemerovo 3
Moscow 3
Nardò 3
Ortona 3
Reggio Emilia 3
Rome 3
San Diego 3
Tokyo 3
Vienna 3
Xiangfen 3
Aberdeen 2
Arzignano 2
Auburn Hills 2
Caprino Veronese 2
Catanzaro 2
Codogno 2
Dubai 2
Düsseldorf 2
Evanston 2
Fiesole 2
Florence 2
Hong Kong 2
Illasi 2
Istanbul 2
Karlstad 2
Kochi 2
Las Vegas 2
Lisbon 2
London 2
Totale 4.814
Salva come PNG Salva come JPEG
Nome #
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia 113
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment naive chronic lymphocytic leukemia 94
Integrated single cell network profiling data of ERK signaling and mutations of SF3B1 gene refine prognosis in chronic lymphocytic leukemia 86
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 85
Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma 85
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 83
Serum levels of soluble CD30 improve international prognostic score in predicting the outcome of advanced Hodgkin's lymphoma 81
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma 80
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 80
Toxoplasma Gondii encephalitis in two allogeneic bone marrow transplant recipients: an emerging infection after heavy immunosoppressive therapy 78
Computer-based drug management in a bone marrow transplant unit: a suitable tool for multiple prescriptions even in critical conditions 78
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis 76
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. 75
High dose sequential chemotherapy (HDSC) as salvage therapy for patients with malignant lymphomas: prognostic factors and clinical outcomes 71
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia 71
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy 69
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 68
EPSTEIN-BARR VIRUS DNA LOAD IN CHRONIC LYMPHOCYTIC LEUKEMIA IS AN INDEPENDENT PREDICTOR OF CLINICAL COURSE AND SURVIVAL 67
B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities 67
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 66
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma 66
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival 66
B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia 64
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. 63
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 63
Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? 62
Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. 60
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 59
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice 59
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program 58
Life-Threatening Protein-Losing Enteropathy Due To Human Cytomegalovirus Infection Upon Immunochemotherapy 58
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 57
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis 57
Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome 55
Computerized drug management in a Bone Marrow Transplant Unit: towards an improvement of hospital drug management 54
Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? 54
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 54
Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases 54
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia 53
Primary Pancreatic Lymphoma: Clinical Presentation, Diagnosis, Treatment and Outcome 53
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? 52
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia 51
Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia 51
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 51
Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status 51
Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease 49
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation 49
Bendamustine plus rituximab: is it a BRIGHT idea? 49
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 49
Computer-based drug management in a bone marrow transplant unit:a suitable tool for multiple prescriptions even in critical conditions 48
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy 48
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia 48
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi 48
P53 and p21waf1 expression by immunohistochemistry in diffuse large B-cell lymphoma has a strong and independent impact on survival of patients with germinal center phenotype 47
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 47
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 47
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 46
Autoimmune cytopenias in chronic lymphocytic leukemia 46
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma 46
Mantle cell lymphoma patients in first relapse: we pretty much know what to do 46
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease 45
Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia 45
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 45
Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment 44
A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks 44
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma 43
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 43
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review 43
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 42
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 42
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL 42
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study 42
The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine 42
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 41
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study 41
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma 39
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma 38
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma 38
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 38
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 38
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma 37
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP 37
The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines 37
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 37
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 37
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program 37
Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12 37
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 37
Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma 37
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries 36
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation 36
Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement 36
Genetic and phenotypic attributes of splenic marginal zone lymphoma 36
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 36
Progressive multifocal leuconcephalopathy and autoimmune haemolytic anemia in chronic lymphocytic leukaemia: more than a fortuitous combination? 35
Immune thrombocytopenia in lymphoproliferative disorders 35
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 35
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 34
miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy 34
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy 33
Totale 5.265
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.360
article - articoli 29.082
book - libri 0
conference - conferenze 1.278
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.720
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020884 147 19 11 27 47 132 36 108 30 88 72 167
2020/20211.268 167 224 29 273 144 169 6 18 24 20 141 53
2021/2022927 52 198 17 47 35 27 47 65 35 31 59 314
2022/20232.029 170 173 213 277 189 531 32 117 218 19 52 38
2023/20241.104 41 94 83 105 101 215 50 109 12 36 181 77
2024/202531 31 0 0 0 0 0 0 0 0 0 0 0
Totale 6.870